• Sobi to refile Gamifant following CHMP rejection pharmatimes
    July 28, 2020
    Sobi has announced its intent to file for a re-examination of Gamifant (emapalumab) in Europe following negative opinion by the European Medicines Agency's human medicines committee.
PharmaSources Customer Service